February 15, 2021
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
February 10, 2021
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
FEBRUARY 10, 2021
Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth
February 3, 2021
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
February 3, 2021
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing
January 20, 2021
Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United-States
JANUARY 19, 2021
Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19
JANUARY 19, 2021
Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States
January 7, 2021
Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021
December 16, 2020
Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia